4
Changes in Ownership
Axsome Therapeutics, Inc. Filed Acc 0000950170-25-021716
Chief Financial Officer sold 15,000 shares at an average $130.10 ($1,951,530)
- Chief Financial Officer acquired 15,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Pizzie Nick Chief Financial Officer | 2025-02-13 | Option exercise 10b5-1 | +12,000 | $3.50 | $42,000 | 54,187 | D: show line 1 in the form |
| Pizzie Nick Chief Financial Officer | 2025-02-13 | Sale 10b5-1 | −12,000 | $129.86 | $1,558,320 | 42,187 | D: show line 2 in the form |
| Pizzie Nick Chief Financial Officer | 2025-02-14 | Option exercise 10b5-1 | +3,000 | $3.50 | $10,500 | 45,187 | D: show line 3 in the form |
| Pizzie Nick Chief Financial Officer | 2025-02-14 | Sale 10b5-1 | −3,000 | $131.07 | $393,210 | 42,187 | D: show line 4 in the form |
| Open-market sales · 15,000 sh · avg $130.10 · $1,951,530 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Pizzie Nick Chief Financial Officer | 2025-02-13 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −12,000 | $3.50 | $42,000 | 0 | D: show line 5 in the form |
| Pizzie Nick Chief Financial Officer | 2025-02-14 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −3,000 | $3.50 | $10,500 | 0 | D: show line 6 in the form |
Loading xslF345X05/ownership.xml…